WPP Media and Criteo Launch First-of-Its-Kind Activation using Open Intelligence to Scale Commerce Signals in CTV
NEW YORK , July 29, 2025 /PRNewswire/ — Today, Criteo (Nasdaq: CRTO), the global platform connecting the commerce ecosystem, announced a new partnership with WPP Media to scale commerce intelligence to Connected TV (CTV). Through the combination of WPP Media's Open Intelligence, its scaled relationships with premium supply partners, and Criteo's real-time commerce signals, advertisers are now able to reach qualified consumers at scale across premium CTV inventory.
Turning Brand Budgets into Business Outcomes in any DSP
As brands increasingly aim to hold all marketing investments accountable to business outcomes, advertisers need smarter ways to connect with audiences across channels like CTV. This collaboration offers a turnkey solution: curated audiences based on high-fidelity commerce signals enhanced and scaled by Open Intelligence—activated in any Demand-side Platform (DSP).
Powered by Criteo's Commerce Grid Supply-side Platform (SSP), curated Deal IDs enable advertisers to seamlessly activate commerce-first CTV strategies across the DSP of their choice, connecting ad exposure to measurable outcomes like foot traffic and sales.
'There is a confluence occurring where traditional brand ambitions of reach and frequency are being met with the fast-emerging metrics of performant commerce media. By combining the strength of Criteo's commerce signals with Open Intelligence, we're accelerating the assimilation of the two—unlocking full-funnel, performance-driven strategies in CTV,' said Sandy Welsch, Executive Director Global Commerce Partnerships & Tech Enablement at WPP Media.
Bringing Commerce and Premium Supply Together
Criteo's real-time commerce signals originate from 17,000 e-commerce sites, 200 global retail partners, and thousands of open web publishers, spanning over $1 trillion in annual ecommerce sales. Amplifying those signals through WPP Media's Open Intelligence creates high-intent, shopper audiences built to convert. As Criteo delivers these audiences against premium CTV inventory, brands are now able to access these segments across their preferred DSP partners, streamlining activation.
'With Commerce Grid, Criteo is giving advertisers a seamless way to activate high-performing audiences on Roku. We're excited to see this partnership showcase the power of CTV in helping brands drive full-funnel outcomes,' said Lindsay Pullins, Director, Head of Business Development & Partnerships, Commerce and Performance at Roku.
'This partnership is about more than better targeting. It's about giving brands the ability to reach broad audiences with the same level of precision and measurability they expect from digital,' said Joseph Meehan, General Manager, Global Commerce Supply at Criteo. 'By combining the unique strengths of each company into one streamlined solution, we're giving brands a smarter way to activate high-intent audiences and transform CTV into a true performance channel.'
Contacts
Criteo Public Relations Jessica Meyers, j.meyers@criteo.com
Criteo Investor Relations Melanie Dambre, m.dambre@criteo.com
About CriteoCriteo (NASDAQ: CRTO) is the global platform connecting the commerce ecosystem for brands, agencies, retailers, and media owners. Its AI-powered advertising platform has unique access to more than $1 trillion in annual commerce sales—powering connections with shoppers, inspiring discovery, and enabling highly personalized experiences. With thousands of clients and partnerships spanning global retail to digital commerce, Criteo delivers the technology, tools, and insights businesses need to drive performance and growth. For more information, please visit criteo.com.
About WPP MediaWPP Media is WPP's global media collective. In a world where media is everywhere and in everything, we bring the best platform, people, and partners together to create limitless opportunities for growth. For more information, visit wppmedia.com.
Forward Looking Statements Disclosure
This press release contains forward-looking statements, including our expectations regarding our market opportunity and future growth prospects and other statements that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially. Factors that might cause or contribute to such differences include, but are not limited to: failure related to our technology and our ability to innovate and respond to changes in technology, uncertainty regarding our ability to access a consistent supply of internet display advertising inventory and expand access to such inventory, investments in new business opportunities and the timing of these investments, whether the projected benefits of acquisitions or strategic transactions materialize as expected, uncertainty regarding international operations and expansion, including related to changes in a specific country's or region's political or economic conditions (such as changes in or new tariffs), the impact of competition or client in-housing, uncertainty regarding legislative, regulatory or self-regulatory developments regarding data privacy matters and the impact of efforts by other participants in our industry to comply therewith, the impact of consumer resistance to the collection and sharing of data, our ability to access data through third parties, failure to enhance our brand cost-effectively, recent growth rates not being indicative of future growth, client flexibility to increase or decrease spend, our ability to manage growth, potential fluctuations in operating results, our ability to grow our base of clients, and the financial impact of maximizing Contribution ex-TAC, as well as risks related to future opportunities and plans, including the uncertainty of expected future financial performance and results and those risks detailed from time-to-time under the caption 'Risk Factors' and elsewhere in the Company's SEC filings and reports, including the Company's Annual Report on Form 10-K filed with the SEC on February 28, 2025, and in subsequent Quarterly Reports on Form 10-Q as well as future filings and reports by the Company. Importantly, at this time, macro-economic conditions including inflation and fluctuating interest rates in the U.S. have impacted and may continue to impact Criteo's business, financial condition, cash flow and results of operations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Barnama
5 hours ago
- Barnama
Datavault AI Debuts Enterprise Commercialization For AI Agents Built With IBM watsonx For AI-powered Data Monetization
BEAVERTON, Ore., July 30 (Bernama) -- via IBN – Datavault AI Inc. (Nasdaq: DVLT), a leader in AI data experience, valuation, and monetization, today announced the expanded commercialization of its flagship AI agents—DataScore® and DataValue®— built with IBM IBM is also committing AI engineering talent and deep technical expertise over multiple years to help Datavault expand and accelerate the impact of its offerings for clients. The integration is designed to help customers streamline their enterprise financial modeling, risk assessment, and pricing strategies across on-premises, cloud, and hybrid environments. Datavault AI is a Platinum partner in IBM's Partner Plus program, with plans to collaborate on deployment, testing, and development to help accelerate AI adoption across key industries including finance, healthcare, sports, entertainment, and government.
New Straits Times
7 hours ago
- New Straits Times
Equities close lower as earnings weigh; Fed statement on tap
NEW YORK: US stocks closed lower on Tuesday as the S&P 500 and Nasdaq retreated from record highs after some disappointing corporate earnings, while investors awaited a Federal Reserve policy statement. A host of Dow components reported earnings, with UnitedHealth, Boeing and Merck all closing lower after their quarterly results. Health insurer UnitedHealth stumbled 7.5 per cent and was the biggest drag on the Dow after a disappointing profit forecast, while Boeing declined 4.4 per cent despite reporting a smaller second-quarter loss. Merck dipped 1.7 per cent after the drugmaker reported quarterly results and said it was extending its pause on shipments of HPV vaccine Gardasil to China until at least the end of 2025 due to persistent weakness in demand. "Earnings have been a bit of a mix. Economic data has been somewhat mixed too, but not enough to move the needle in terms of the Fed," said Tim Ghriskey, senior portfolio strategist at Ingalls & Snyder in New York. "The next two days, you have Microsoft, Meta, Apple, Amazon - those are big companies, and they will move markets depending on how the earnings are and how the outlooks are." Earnings from megacaps Meta, Microsoft, Amazon and Apple are due this week and are likely to have a strong influence on market direction due to their large market weightings. The Dow Jones Industrial Average fell 204.57 points, or 0.46 per cent, to 44,632.99, the S&P 500 lost 18.91 points, or 0.30 per cent, to 6,370.86 and the Nasdaq Composite lost 80.29 points, or 0.38 per cent, to 21,098.29. United Parcel Service shares plunged 10.6 per cent as the package delivery company posted earnings and again declined to issue annual revenue and margin forecasts, deepening concerns that US President Donald Trump's continually changing trade policy is weighing on the company. That helped drag down the Dow Jones Transport Average by 2.3 per cent for its biggest daily percentage decline since May 21. Likewise, Whirlpool plummeted 13.4 per cent after the home appliances maker slashed its annual earnings forecast and dividend, citing pressure from a pull-forward in imports by rivals ahead of Trump's tariffs. Procter & Gamble shares shed 0.3 per cent, as the maker of consumer goods such as dish soap and toilet paper forecast annual results below estimates and said it would raise prices on some products to offset the tariff impact. Nearly 200 S&P 500 components have reported earnings and are posting results 6.4 per cent above expectations, according to LSEG data, compared with an average of 6.3 per cent over the last four quarters. On the economic front, consumer confidence in July increased more than expected to 97.2. In June, US job openings and hiring, or JOLTS data, had decreased, pointing to a further slowdown in labor market activity. The JOLTS report was the first in a string of data on the labor market this week, culminating in Friday's government payrolls report. The Fed is largely expected to leave rates unchanged at its policy announcement on Wednesday. Remarks by Fed Chair Jerome Powell will be closely monitored to gauge the timing of any potential rate cuts. Key negotiations between the US and China completed their second day in Stockholm as the world's two leading economies aim to resolve their trade conflict, with Trump saying he was told by Treasury Secretary Scott Bessent that the latter had a very good meeting with Chinese officials. Declining issues outnumbered advancers by a 1.03-to-1 ratio on the NYSE and by a 2.08-to-1 ratio on the Nasdaq. The S&P 500 posted 32 new 52-week highs and nine new lows, while the Nasdaq Composite recorded 76 new highs and 83 new lows. Volume on US exchanges was 18.01 billion shares, compared with the 17.89 billion average for the full session over the last 20 trading days.
Malaysian Reserve
7 hours ago
- Malaysian Reserve
Telix H1 2025 Results: Investor Webcast Notification
MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix') today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025. An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025). Participants can register for the webcast at the following link: Participants can register for the teleconference here: About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Visit for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook Telix Investor RelationsMs. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Telix Investor Relations (U.S.) Annie Kasparian Telix Pharmaceuticals Limited Director Investor Relations and Corporate Communications Email: This announcement has been authorized for release by Telix Pharmaceuticals Limited's Company Secretary, Genevieve Ryan. Legal Notices Cautionary Statement Regarding Forward-Looking Statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. ©2025 Telix Pharmaceuticals Limited. All rights reserved.
